miRNAs: Critical mediators of breast cancer metastatic programming

Nair, Madhumathy G.; Somashekaraiah, Vidya M.; Ramamurthy, Vishakha; Prabhu, Jyothi S; Sridhar, T.S.

doi:10.1016/j.yexcr.2021.112518

Cited by 7 publications

(6 citation statements)

References 230 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRNAs) are formed by a single-stranded non-coding RNA with 19-24 nucleotides and can often act as tumor suppressors or promoters [117,118]. miRNAs act in the regulation of cell-cell and cell-extracellular matrix adhesion molecules promoting local infiltration and dissemination of tumor cells in the systemic circulation [119] and have been suggested as possible cancer biomarkers.…”

Section: Micrornasmentioning

confidence: 99%

“…Zhang et al [123] revealed that increased expression of miR-1246 and miR-155 in BC patients is predictive for trastuzumab therapy resistance, which is evidence of it being a clinical prognostic marker [123]. Nair et al [119] shows the importance of miRNAs for BC diagnosis and prognosis, suggesting the use of a BC-specific miRNAs panel as a clinical assessment of microRNAs levels [119].…”

Section: Micrornasmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in Breast Cancer: An Old Story with a New End

Alves

Meira

Merigueti

et al. 2023

Genes

View full text Add to dashboard Cite

Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease and the leading cause of cancer mortality in women. Advances in molecular technologies allowed for the identification of new and more specifics biomarkers for breast cancer diagnosis, prognosis, and risk prediction, enabling personalized treatments, improving therapy, and preventing overtreatment, undertreatment, and incorrect treatment. Several breast cancer biomarkers have been identified and, along with traditional biomarkers, they can assist physicians throughout treatment plan and increase therapy success. Despite the need of more data to improve specificity and determine the real clinical utility of some biomarkers, others are already established and can be used as a guide to make treatment decisions. In this review, we summarize the available traditional, novel, and potential biomarkers while also including gene expression profiles, breast cancer single-cell and polyploid giant cancer cells. We hope to help physicians understand tumor specific characteristics and support decision-making in patient-personalized clinical management, consequently improving treatment outcome.

show abstract

Section: Micrornasmentioning

confidence: 99%

Section: Micrornasmentioning

confidence: 99%

Biomarkers in Breast Cancer: An Old Story with a New End

Alves

Meira

Merigueti

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

“…Being a hotspot for a long time, many miRNAs have been reported to involve in regulating the oncogenesis and progression of human cancers [ 32 – 34 ]. MiR-613 has been identified as a significant suppressor in multiple cancers, including gastric cancer [ 35 ], bladder cancer [ 36 ], and BrCa [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

YWHAZ interacts with DAAM1 to promote cell migration in breast cancer

Mei

Liu

et al. 2021

Cell Death Discov.

View full text Add to dashboard Cite

Dishevelled-associated activator of morphogenesis 1 (DAAM1) is a critical driver in facilitating metastasis in breast cancer (BrCa). However, molecular mechanisms for the regulation of DAAM1 activation are only partially elucidated. In this research, the expression levels of YWHAZ and DAAM1 were examined by immunohistochemistry (IHC) staining in BrCa tissues. The functional roles of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ)–DAAM1 axis and their regulator microRNA-613 (miR-613) in BrCa cells and associated molecular mechanisms were demonstrated in vitro. As results, the expression levels of DAAM1 and YWHAZ were significantly upregulated in BrCa tissues compared with normal tissues and remarkably associated with poor prognosis. Besides, DAAM1 and YWHAZ were positively correlated with each other in BrCa tissues. YWHAZ interacted and colocalized with DAAM1 in BrCa cells, which was essential for DAAM1-mediated microfilament remodeling and RhoA activation. Moreover, miR-613 directly targeted both YWHAZ and DAAM1, contributing to inhibiting BrCa cells migration via blocking the complex of YWHAZ–DAAM1. To sum up, these data reveal that YWHAZ regulates DAAM1 activation, and the YWHAZ–DAAM1 complex is directly targeted by the shared post-transcriptional regulator miR-613.

show abstract

“…These results may indicate an interrelation between the miRNA profile and the ability to metastasize in different host organs in mRCC, which could cause organotropism in metastatic settlement. The fact that an SSM triggered by the profile of miRNAs (transported by EV to the potential premetastatic sites, see Section 3.2 (a) can in principle occur is documented in the literature, at least for more common and, therefore, better-researched tumour entities such as breast cancer metastases [213,214].…”

Section: Epigenetics and Ssm In Ispmrccmentioning

confidence: 98%

Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma

Sellner,

Compérat,

Klimpfinger

2023

IJMS

View full text Add to dashboard Cite

Isolated pancreatic metastases of renal cell carcinoma (IsPMRCC) are a rare manifestation of metastatic, clear-cell renal cell carcinoma (RCC) in which distant metastases occur exclusively in the pancreas. In addition to the main symptom of the isolated occurrence of pancreatic metastases, the entity surprises with additional clinical peculiarities: (a) the unusually long interval of about 9 years between the primary RCC and the onset of pancreatic metastases; (b) multiple pancreatic metastases occurring in 36% of cases; (c) favourable treatment outcomes with a 75% 5-year survival rate; and (d) volume and growth-rate dependent risk factors generally accepted to be relevant for overall survival in metastatic surgery are insignificant in isPMRCC. The genetic and epigenetic causes of exclusive pancreatic involvement have not yet been investigated and are currently unknown. Conversely, according to the few available data in the literature, the following genetic and epigenetic peculiarities can already be identified as the cause of the protracted course: 1. high genetic stability of the tumour cell clones in both the primary tumour and the pancreatic metastases; 2. a low frequency of copy number variants associated with aggressiveness, such as 9p, 14q and 4q loss; 3. in the chromatin-modifying genes, a decreased rate of PAB1 (3%) and an increased rate of PBRM1 (77%) defects are seen, a profile associated with a favourable course; 4. an increased incidence of KDM5C mutations, which, in common with increased PBRM1 alterations, is also associated with a favourable outcome; and 5. angiogenetic biomarkers are increased in tumour tissue, while inflammatory biomarkers are decreased, which explains the good response to TKI therapy and lack of sensitivity to IT.

show abstract

miRNAs: Critical mediators of breast cancer metastatic programming

Cited by 7 publications

References 230 publications

Biomarkers in Breast Cancer: An Old Story with a New End

Biomarkers in Breast Cancer: An Old Story with a New End

YWHAZ interacts with DAAM1 to promote cell migration in breast cancer

Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About